Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.
Sourris KC, Ding Y, Maxwell SS, Al-Sharea A, Kantharidis P, Mohan M, Rosado CJ, Penfold SA, Haase C, Xu Y, Forbes JM, Crawford S, Ramm G, Harcourt BE, Jandeleit-Dahm K, Advani A, Murphy AJ, Timmermann DB, Karihaloo A, Knudsen LB, El-Osta A, Drucker DJ, Cooper ME, Coughlan MT.
Sourris KC, et al. Among authors: jandeleit dahm k.
Kidney Int. 2024 Jan;105(1):132-149. doi: 10.1016/j.kint.2023.09.029. Epub 2023 Dec 8.
Kidney Int. 2024.
PMID: 38069998
Free article.